预约演示
RS BioTherapeutics Appoints Michelle L. Shuffett, MD as SVP of Medical and Scientific Affairs
2023-06-05
高管变更
RS BioTherapeutics Appoints Michelle L. Shuffett, MD as SVP of Medical and Scientific Affairs
CUMBERLAND, Md., June 05, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life changing medications, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Senior Vice President of Medical and Scientific Affairs.
Dr. Shuffett attended medical school at the University of Kentucky, completed her residency at UCLA Mattel Children's Hospital, and practiced at Children's Hospital Los Angeles. She began her career in the pharmaceutical industry at Boehringer Ingelheim, focusing on COPD opinion leader development and advocacy, medical marketing communications, research, and medical-legal review. During that time, she also attended the London School of Economics and earned certifications in Healthcare Economics and Quantitative Analysis.
Dr. Shuffett has also served in senior roles at several organizations including Synapse Medical Communications, Everyday Health, Columbia Care, and Radicle Science. She also founded her own consulting firm, Sea Sprite International Ltd. in 2018 and currently serves as an advisory board member for the 100 Million Ways Foundation and Maavee.
Commenting on the appointment of Dr. Shuffett, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “We are very pleased to welcome Michelle as Senior Vice President of Medical and Scientific Affairs. Her diverse experience as a physician, consultant, marketer, entrepreneur, and board member, makes her a valuable addition to our leadership team. I look forward to working closely with Michelle as we continue to develop RSBT-001 as an alternative to corticosteroids for patients suffering from COPD. Her experience with COPD will be invaluable in this endeavor.”
Commenting on her appointment, Dr. Shuffett said, “I’m very excited to join Dean and the rest of the talented leadership team at RS BioTherapeutics in the development of breakthrough pharmaceutical medicines to address both chronic and acute pulmonary inflammation. We have a tremendous opportunity to help patients manage and improve their health conditions.”
About RS BioTherapeutics
RS BioTherapeutics’ mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life-changing medicines. RS BioTherapeutics’ first investigational compound (RSBT-001) is a patent-pending, semi-synthetic cannabidiolic acid complex in development as an alternative to corticosteroids in addressing exacerbation and preventing progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com.
Media Contact:
David Gutierrez, Dresner Corporate Services for RS BioTherapeutics, (312) 780-7204, dgutierrez@dresnerco.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/372ee2dd-5430-4c5d-b7e9-1c729135403a
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。